About Rubedo Life Sciences

Rubedo Life Sciences develops targeted therapeutics that specifically eliminate pathologic cells responsible for aging, thereby addressing the biological mechanisms that contribute to chronic diseases. Their approach aims to enhance health span by maintaining cellular youth and reducing the impact of age-related conditions.

```xml <problem> Chronic diseases are often driven by the accumulation of pathologic cells, such as senescent cells, which contribute to aging and tissue dysfunction. Current therapeutic approaches often fail to specifically target and eliminate these problematic cells, limiting their effectiveness in addressing age-related conditions. </problem> <solution> Rubedo Life Sciences is a clinical-stage biotechnology company focused on developing targeted therapies that selectively eliminate pathologic cells responsible for driving aging and chronic diseases. The company's approach centers on modulating key pathways, such as GPX4, within these cells to promote their clearance and restore tissue homeostasis. Rubedo's lead drug candidate, RLS-1496, is a first-in-class GPX4 modulator designed to target senescent cells and surrounding tissues. Their discovery platform, ALEMBIC™, identifies relevant cell types in specific disease contexts, enabling the development of therapeutics that enhance healthspan by addressing the underlying biological mechanisms of aging. </solution> <features> - Development of therapeutics targeting pathologic senescent cells to treat age-related diseases. - Lead drug candidate RLS-1496, a GPX4 modulator, currently in Phase 1 clinical trials. - ALEMBIC™ drug discovery platform for identifying senescent cells in specific disease contexts. - Focus on restoring tissue homeostasis by eliminating dysfunctional cells. - Multi-year partnership with Beiersdorf to develop skincare products addressing cellular aging. </features> <target_audience> The primary target audience includes individuals suffering from age-related chronic diseases, as well as pharmaceutical companies and research institutions focused on longevity and regenerative medicine. </target_audience> ```

What does Rubedo Life Sciences do?

Where is Rubedo Life Sciences located?

Rubedo Life Sciences is based in Sunnyvale, United States.

When was Rubedo Life Sciences founded?

Rubedo Life Sciences was founded in 2018.

How much funding has Rubedo Life Sciences raised?

Rubedo Life Sciences has raised 52000000.

Location

Sunnyvale, United States

Founded

2018

Funding

52000000

Employees

31 employees

Major Investors

Khosla Ventures, Ahren Innovation Capital

Find Investable Startups and Competitors

Search thousands of startups using natural language

AI voice (2021+)underground pipe robots energy flexibility software

Start Searching

Rubedo Life Sciences

⚠️ AI-generated overview based on web search data – may contain errors, please verify information yourself! You can claim this account with your email domain to make edits.

Executive Summary

rubedolife.com 5K+

Crunchbase

Founded 2018 – Sunnyvale, United States

Funding

Estimated Funding

$50M+

Major Investors

Khosla Ventures, Ahren Innovation Capital

Team (30+)

No team information available.

Company Description

Problem

Chronic diseases are often driven by the accumulation of pathologic cells, such as senescent cells, which contribute to aging and tissue dysfunction. Current therapeutic approaches often fail to specifically target and eliminate these problematic cells, limiting their effectiveness in addressing age-related conditions.

Solution

Rubedo Life Sciences is a clinical-stage biotechnology company focused on developing targeted therapies that selectively eliminate pathologic cells responsible for driving aging and chronic diseases. The company's approach centers on modulating key pathways, such as GPX4, within these cells to promote their clearance and restore tissue homeostasis. Rubedo's lead drug candidate, RLS-1496, is a first-in-class GPX4 modulator designed to target senescent cells and surrounding tissues. Their discovery platform, ALEMBIC™, identifies relevant cell types in specific disease contexts, enabling the development of therapeutics that enhance healthspan by addressing the underlying biological mechanisms of aging.

Features

Development of therapeutics targeting pathologic senescent cells to treat age-related diseases.

Lead drug candidate RLS-1496, a GPX4 modulator, currently in Phase 1 clinical trials.

ALEMBIC™ drug discovery platform for identifying senescent cells in specific disease contexts.

Focus on restoring tissue homeostasis by eliminating dysfunctional cells.

Multi-year partnership with Beiersdorf to develop skincare products addressing cellular aging.

Target Audience

The primary target audience includes individuals suffering from age-related chronic diseases, as well as pharmaceutical companies and research institutions focused on longevity and regenerative medicine.